SCHEMBL691489

SCHEMBL691489

CC1(C)CC2CC[C]1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10618370 0.86
SCHEMBL1008111 0.63
SCHEMBL16241619 0.56
SCHEMBL6277862 0.54
SCHEMBL11353484 0.54
SCHEMBL1929781 0.54
SCHEMBL737627 0.51
SCHEMBL7954 0.50
SCHEMBL5760574 0.49
SCHEMBL135915 0.49

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4125484-A Tertiary alcohols SHELL OIL COMPANY (US) 1978-11-14 US claimed
US-20240238438-A1 CD-90 Targeted Lipid Nanoparticles FRED HUTCHINSON CANCER CENTER 2024-07-18 US disclosed
US-20240226310-A1 Lipid Nanoparticle Therapeutics that Evade the Immune Response THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2024-07-11 US disclosed
US-20240216523-A1 Compositions and Methods for Targeting Lipid Nanoparticle Therapeutics to Stem Cells NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-07-04 US disclosed
WO-2024137663-A2 TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-06-27 WO disclosed
US-12012395-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2024-06-18 US disclosed
WO-2024124143-A2 HSC TARGETED LNP FOR DELIVERY OF PRO-APOPTOTIC MRNA AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-06-13 WO disclosed
US-20240189445-A1 Targeted Therapeutic Lipid Nanoparticles and Methods of Use NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-13 US disclosed
WO-2024118979-A1 TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-06-06 WO disclosed
US-20240175023-A1 GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY EMPIRICO INC. 2024-05-30 US disclosed
WO-2011116161-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS INC. (US) 2011-09-22 WO disclosed
US-20110230487-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. 2011-09-22 US disclosed
WO-2011109345-A1 ISOTOPICALLY ENRICHED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2011-09-09 WO disclosed
US-20110218207-A1 ISOTOPICALLY ENRICHED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
EP-2265611-A1 TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2010-12-29 EP disclosed
US-20100273795-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 US disclosed
WO-2010123960-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 WO disclosed
WO-2009112832-A1 TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2009-09-17 WO disclosed
EP-0379110-A2 Silver halide color photographic light-sensitive material KONICA CORPORATION (JP) 1990-07-25 EP disclosed
US-4125484-A Tertiary alcohols SHELL OIL COMPANY (US) 1978-11-14 US disclosed